Home > Haematology > EHA 2020 > Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin in adult patients with relapsed/refractory classic Hodgkin lymphoma, meeting one of the dual primary endpoints.

Prof. Pier Luigi Zinzani (University of Bologna, Italy) presented the results of the randomised phase 3 KEYNOTE-204 study, which compared the efficacy and safety of pembrolizumab with that of brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) [1].

Patients (n=304) with R/R cHL were randomly assigned 1:1 to receive intravenous pembrolizumab at 200 mg every 3 weeks for up to 35 cycles or brentuximab vedotin at 1.8 mg/kg every 3 weeks for up to 35 cycles. Patients included had had prior autologous SCT or were ineligible for autologous SCT, had measurable disease, and Eastern Cooperative...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on